Further studies have found that such DTCs experiencing hypoxia are more likely to activate nuclear receptor subfamily 2 group F member 1 gene (NR2F1)-dependent dormant programs, thereby evading chemotherapy-induced apoptosis, suggesting that hypoxia within the primary tumor may be an important cause of treatment tolerance and recurrence 45. Here, NR2F1 is linked to neoplasm.